Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.
about
Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.Androgen receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.Height, obesity, and the risk of TMPRSS2:ERG-defined prostate cancer.
P2860
Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Androgen receptor CAG repeat l ...... state Cancer Prevention Trial.
@ast
Androgen receptor CAG repeat l ...... state Cancer Prevention Trial.
@en
type
label
Androgen receptor CAG repeat l ...... state Cancer Prevention Trial.
@ast
Androgen receptor CAG repeat l ...... state Cancer Prevention Trial.
@en
prefLabel
Androgen receptor CAG repeat l ...... state Cancer Prevention Trial.
@ast
Androgen receptor CAG repeat l ...... state Cancer Prevention Trial.
@en
P2093
P2860
P1433
P1476
Androgen receptor CAG repeat l ...... ostate Cancer Prevention Trial
@en
P2093
Adrie van Bokhoven
Cathee Till
Catherine M Tangen
Cindy H Chau
Douglas K Price
Ian M Thompson
M Scott Lucia
Marileila Varella-Garcia
Phyllis J Goodman
Robin J Leach
P2860
P304
P356
10.1016/J.UROLOGY.2014.03.015
P407
P577
2014-05-10T00:00:00Z